2006
DOI: 10.1097/01.qai.0000214808.75594.73
|View full text |Cite
|
Sign up to set email alerts
|

Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin Coadministration

Abstract: We studied the effect of rifampicin on steady-state pharmacokinetics of nevirapine and the impact of increasing the dose of nevirapine on its peak (Cmax) and trough (Cmin) levels in 13 HIV-infected patients on regular antiretroviral treatment with nevirapine-containing regimens (200 mg twice daily). A baseline pharmacokinetic study was conducted and repeated after 1 week of daily rifampicin (450/600 mg). The study was repeated in 7 of 8 patients who had subtherapeutic Cmin nevirapine levels after increasing ne… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
32
1
1

Year Published

2008
2008
2020
2020

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 51 publications
(38 citation statements)
references
References 17 publications
4
32
1
1
Order By: Relevance
“…In our study, rifampicin induced the metabolism of nevirapine, seen as an increase in its CL/F by 37.4%, which is in agreement with previous reports of rifampicin altering the pharmacokinetics of nevirapine [4,9,10,12,13]. This may be due to the induction of CYP3A4 and CYP2B6 leading to an enhancement of nevirapine metabolism.…”
Section: Discussionsupporting
confidence: 81%
See 2 more Smart Citations
“…In our study, rifampicin induced the metabolism of nevirapine, seen as an increase in its CL/F by 37.4%, which is in agreement with previous reports of rifampicin altering the pharmacokinetics of nevirapine [4,9,10,12,13]. This may be due to the induction of CYP3A4 and CYP2B6 leading to an enhancement of nevirapine metabolism.…”
Section: Discussionsupporting
confidence: 81%
“…The mutation is observed after 4 weeks of monotherapy and may occur in just 2 weeks if viral replication is not well controlled in the presence of nevirapine [4]. Several reports on the effect of rifampicin on nevirapine pharmacokinetics have been published [4,[9][10][11][12][13][14]. However, to our knowledge this is the first modelling report on the effect of rifampicin on nevirapine pharmacokinetics in South African patients.…”
Section: Introductionmentioning
confidence: 64%
See 1 more Smart Citation
“…This combination is considered absolutely contraindicated McCance-Katz et al, 2006;Matteelli et al, 2007a;Ramachandran et al, 2006;Ribera et al, 2001) Delavirdine (Borin et al, 1997;DeJong et al 2004;McCance-Katz et al, 2006;Spradling et al, 2002) Nevirapine (Benator et al, 2007;Blumberg et al, 2003;Borin et al, 1997;Burger et al, 2006;Hamzeh et al, 2003;Kraft et al, 2004;La Porte et al, 2004;Polk et al, 2001;Ramachandran et al, 2006;Ribera et al, 2001Ribera et al, , 2007Rolla et al, 2006) 2: high risk 3: medium risk…”
Section: : Very High Riskmentioning
confidence: 99%
“…(DHSS, 2011) Rifampicin and NNRTI. (Finch et al, 2002;de Jong et al, 2004;Ribera et al, 2001;Ramachandran et al, 2006;Weiner et al, 2005) In general, the use of rifampicin together with delavirdine is considered contraindicated (Borin et al, 1997) (level 1: very high risk).…”
Section: Interactions Of Rifamycins With Protease Inhibitors (Pis) Ormentioning
confidence: 99%